Remarkable Response in Refractory Multiple Myeloma After CAR-T Cell Therapy

Patient Profile Mr. Mohamed H., 70-year-old male from Egypt

Initial Diagnosis Multiple myeloma with widespread skeletal involvement. Pre-treatment PET/CT (July 2024) showed extensive hypermetabolic bone lesions throughout the axial and appendicular skeleton, with multiple destructive lesions and a maximum SUV of 17.9, indicating highly active disease.

Treatment After progressing on conventional chemotherapy, Mr. Mohamed sought advanced options and chose Bioocus for targeted CAR-T cell immunotherapy.

Follow-up Results (September 2024 – only ~2 months post-therapy) Repeat whole-body PET/CT revealed:

• Dramatic reduction in metabolic activity across nearly all previously active lesions
• Many lesions completely resolved (no abnormal FDG uptake)
• Maximum SUV dropped from 17.9 to 5.16
• Only mild diffuse marrow uptake remained, consistent with post-treatment reactive changes
• No new hypermetabolic foci in bone or soft tissue

Mr. Mohamed became completely asymptomatic shortly after infusion. He reports regained strength, no bone pain, and a return to normal daily life — outcomes he describes as “a second chance.”

“Before the pain was everywhere, and I thought this was the end. After the CAR-T treatment at Bioocus, I feel like a new person. The latest scan shows the cancer is almost gone. I am so grateful.” — Mr. Mohamed H.

This case demonstrates the powerful potential of CAR-T therapy in achieving rapid and deep responses, even in elderly patients with advanced, heavily pre-treated multiple myeloma.